Published in N Engl J Med on February 03, 2011
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (2011) 3.90
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst (2015) 2.18
Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother (2016) 2.07
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Focus on research: weighing the benefits and costs of HPV vaccination of young men. N Engl J Med (2011) 1.97
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Human papillomavirus virus (HPV) genotype- and age-specific analyses of external genital lesions among men in the HPV Infection in Men (HIM) Study. J Infect Dis (2014) 1.60
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis (2012) 1.48
Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) (2012) 1.46
Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ (2015) 1.43
The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med (2011) 1.40
Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis (2013) 1.33
Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev (2012) 1.33
Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol (2012) 1.29
The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis (2011) 1.24
Genital HPV infection and related lesions in men. Prev Med (2011) 1.19
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer (2013) 1.08
Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol (2012) 1.06
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis (2014) 1.06
Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis (2011) 1.05
Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res (2011) 1.05
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis (2011) 1.05
Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer (2011) 1.03
Multiple human papillomavirus infections and type competition in men. J Infect Dis (2011) 1.02
Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health (2013) 1.01
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol (2011) 0.99
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS One (2013) 0.99
Physicians' human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients: a national study. Cancer Epidemiol Biomarkers Prev (2014) 0.99
Primary prevention and vaccination for penile cancer. Ther Adv Urol (2013) 0.99
Designing messages to motivate parents to get their preteenage sons vaccinated against human papillomavirus. Perspect Sex Reprod Health (2012) 0.99
Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med (2015) 0.98
Small molecule inhibitors of human papillomavirus protein - protein interactions. Open Virol J (2011) 0.97
Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol (2012) 0.97
HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect (2013) 0.97
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94
Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br J Cancer (2015) 0.94
Male human papillomavirus prevalence and association with condom use in Brazil, Mexico, and the United States. J Infect Dis (2012) 0.94
The road ahead for cervical cancer prevention and control. Curr Oncol (2014) 0.94
Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. Vaccine (2013) 0.93
Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. CA Cancer J Clin (2015) 0.93
Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines (2014) 0.93
Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncol (2013) 0.92
A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PLoS One (2013) 0.92
Geospatial patterns of human papillomavirus vaccine uptake in Minnesota. BMJ Open (2015) 0.91
Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog (2014) 0.91
Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health (2014) 0.90
Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol (2011) 0.90
HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol (2015) 0.90
Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines (2015) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus Res (2015) 0.89
Review of Gardasil. J Vaccines Vaccin (2010) 0.89
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin (2011) 0.88
Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. Eur Urol (2015) 0.88
Effect of the decision-making process in the family on HPV vaccination rates among adolescents 9-17 years of age. Hum Vaccin Immunother (2014) 0.87
Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med (2015) 0.87
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. Hum Vaccin Immunother (2014) 0.85
HPV-associated Oropharyngeal Cancers--Are They Preventable? Cancer Prev Res (Phila) (2011) 0.85
Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. Clinicoecon Outcomes Res (2013) 0.85
HPV awareness and willingness to HPV vaccination among high-risk men attending an STI clinic in Puerto Rico. P R Health Sci J (2012) 0.85
Incidence of and risk factors for type-specific anal human papillomavirus infection among HIV-positive MSM. AIDS (2014) 0.84
Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014. Infect Chemother (2015) 0.84
Anal human papillomavirus and HIV: A cross-sectional study among men who have sex with men in Moscow, Russia, 2012-2013. Euro Surveill (2015) 0.84
Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One (2014) 0.84
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol (2014) 0.83
Young Hispanic Men and Human Papillomavirus Vaccination Choices. J Transcult Nurs (2014) 0.83
Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) (2014) 0.82
Vaccination against human papilloma virus infection in male adolescents: knowledge, attitudes, and acceptability among parents in Italy. Hum Vaccin Immunother (2014) 0.82
Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio. Vaccine (2012) 0.82
Male circumcision for prevention of oncogenic HPV infection. Lancet (2011) 0.82
Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status. BMC Infect Dis (2015) 0.82
Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health (2012) 0.82
Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect Agent Cancer (2014) 0.81
Prevalence of DNA-HPV in male sexual partners of HPV-infected women and concordance of viral types in infected couples. PLoS One (2012) 0.81
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis (2016) 0.81
Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev (2012) 0.81
Human papillomavirus vaccination: current indications and future directions. Obstet Gynecol Clin North Am (2013) 0.81
Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among men who have sex with men in Hong Kong. PLoS One (2013) 0.81
Human papilloma virus infection in head and neck cancer. Dtsch Arztebl Int (2013) 0.81
Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant (2013) 0.81
Adolescent Male Human Papillomavirus Vaccination. Glob Pediatr Health (2016) 0.80
Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol (2012) 0.80
The prevalence of anal human papillomavirus among young HIV negative men who have sex with men. BMC Infect Dis (2012) 0.80
Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One (2014) 0.80
Role and uptake of human papillomavirus vaccine in adolescent health in the United States. Adolesc Health Med Ther (2011) 0.80
Human papilloma virus vaccines: Current scenario. Indian J Sex Transm Dis (2011) 0.80
The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. Int J STD AIDS (2013) 0.79
Targeted Facebook Advertising is a Novel and Effective Method of Recruiting Participants into a Human Papillomavirus Vaccine Effectiveness Study. JMIR Res Protoc (2016) 0.79
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis (2006) 4.67
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2008) 3.93
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis (2002) 3.42
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis (2008) 2.56
Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect (2009) 2.30
HPV infection in men. Dis Markers (2007) 1.57
Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas. J Med Virol (2006) 1.54
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Loss of vaccine-induced immunity to varicella over time. N Engl J Med (2007) 4.55
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
[A man in his 30s with urethral discharge and dysuria]. Tidsskr Nor Laegeforen (2014) 3.67
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis (2012) 3.19
IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood (2009) 3.14
Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ (2011) 2.95
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer (2009) 2.90
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72
Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst (2007) 2.68
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 2.58
Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol (2006) 2.56
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun (2006) 2.41
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 2.33
Representing the profession. Vet Rec (2008) 2.28
Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis (2004) 2.24
Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis (2002) 2.22
Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med (2008) 2.22
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis (2004) 2.21
Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med (2003) 2.21
Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med (2010) 2.17
Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology (2004) 2.16
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol (2006) 1.96
HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis (2011) 1.95
Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis (2006) 1.94
HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol (2010) 1.90
Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis (2009) 1.89
Postinfancy growth, schooling, and cognitive achievement: Young Lives. Am J Clin Nutr (2013) 1.88
A cross-national study of subjective sexual well-being among older women and men: findings from the Global Study of Sexual Attitudes and Behaviors. Arch Sex Behav (2006) 1.87
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA (2005) 1.86
Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis (2010) 1.85
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol (2002) 1.81
Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol (2004) 1.80
High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med (2003) 1.80
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80